Monday September 23, 2019

Gut Bacteria Has The Ability To Contribute to Diabetes

"Our findings show clearly how important the interaction between gut microbiota and diet is to understand our metabolism in health and disease," said Backhed

0
//
Diabetes
According to the researchers, these novel findings may provide the basis for new therapies for patients who have heart disease complicated by diabetes. Pixabay

Gut bacteria has the ability to affect how cells respond to insulin and can thus contribute to Type-2 diabetes, says a new study.

The study explored that the gut microbiota of people with treatment-naive Type-2 diabetes can be linked to a different metabolism of the amino acid histidine, which is mainly derived from the diet.

This in turn leads to the formation of imidazole propionate, a substance that impairs the cells’ ability to respond to insulin. Therefore, reducing the amount of bacterial-produced imidazole propionate could be a new way of treating patients with such disease.

“This substance does not cause all Type-2 diabetes, but our working hypothesis is that there are sub-populations of patients who might benefit from changing their diet or altering their gut microbiota to reduce the levels of imidazole propionate,” said Fredrik Backhed, Professor at the University of Gothenburg in Sweden.

Diabetes
Representational image. Pixabay

For the study, published in the journal Cell, the research team involved 649 participants.

They used fecal samples and found that the microbiota of people with Type-2 diabetes produced imidazole propionate when histidine was added. However, this mechanism was not found in the diabetes-free control subjects.

Also read- Nearly 40 Individual HPV Types Linked to HIV Infection

“Our findings show clearly how important the interaction between gut microbiota and diet is to understand our metabolism in health and disease,” said Backhed.

The result also shows that gut bacteria from different individuals can lead to the production of completely different substances that may have very specific effects in the body,” he noted. (IANS)

Next Story

Diabetes Medication to Reduce Heart Disease Shows Promise: Researchers

The results are applicable primarily to dapagliflozin, which was the predominant SGLT2 inhibitor used in Scandinavia during the study period

0
diabetes
Diabetes is the ninth leading cause of death in women and claims 2.1 million female lives every year, more so than men. Pixabay

Researchers, including one of an Indian-origin, have shed light on how a class of medications that help regulate blood sugar for patients with Type 2 diabetes can also protect from heart disease.

The findings published in the journal Cell Metabolism, focus on the effect of diabetes medication — empagliflozin — on cell repair in blood vessels and the resulting risks of heart disease.

Empagliflozin is a medication that falls under a category of drugs called SGLT2 inhibitors, which lower blood sugar.

“We have seen large-scale clinical trials giving us clear evidence that SGLT2 inhibitors can also protect our patients who have diabetes from heart disease,” said Indian-origin researcher and study author Subodh Verma from St. Michael’s Hospital in Canada.

The research suggests that circulating progenitor cells — which are found in the bone marrow and play a role in heart health — along with inflammatory cells are regulated with this diabetes medication.

For patients who have diabetes are at the risk of heart disease, such medications may provide heart protection by relieving damaged cells that would otherwise perpetuate heart disease by causing faulty vessel repair.

Diabetes
According to the researchers, these novel findings may provide the basis for new therapies for patients who have heart disease complicated by diabetes. Pixabay

Using blood samples from the EMPA-HEART CardioLink-6 Trial, the research team was able to show that in diabetes, regenerative progenitor cells were reduced.

Patients who took empagliflozin, however, these progenitor cells were restored later.

“We found that in people with diabetes, not only were beneficial progenitor cells increased but we saw indications of reduced inflammation and oxidative stress, which can also contribute to cardiovascular disease,” said David Hess, Associate Professor at Western University.

According to the researchers, these novel findings may provide the basis for new therapies for patients who have heart disease complicated by diabetes.

Also Read: Social Networking Giant Facebook Plans Test to Let Users Hide ‘Like’ Counts

Earlier a research from Karolinska Institute in Sweden said that the new type of drugs for type 2 diabetes — SGLT2 inhibitors — are associated with a reduced risk of heart failure by 34 per cent.

The results are applicable primarily to dapagliflozin, which was the predominant SGLT2 inhibitor used in Scandinavia during the study period. (IANS)